Fig. 1From: Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 monthsChanges in bronchial RBM thickness in omalizumab responders (OR) and non-omalizumab responders (NOR) at baseline and after 12 and 36 months of anti-IgE treatmentBack to article page
